The Xiangya Ocular Tumor Bank: A Disease-Specific Biobank for Advancing Translational Research Into Ocular Tumors

Zhaolin Gao, Jia Tan, Sha Wang, Haiyang Yu, Ziyu Zhou, Yun Zhang, Mushi Zhou, Xiaobo Xia, Fei Yao, Jufang HuangFrontiers in Medicine 2022 · DOI

Introduction

Ocular tumors, though relatively rare, present significant clinical challenges, often leading to severe vision impairment or mortality. Understanding the pathogenesis and etiology of these conditions—ranging from pediatric retinoblastoma to adult uveal melanoma—is critical for developing effective diagnostic and therapeutic strategies. However, research has been historically limited by a shortage of high-quality human eye tissue and the inability of animal models to fully replicate human tumor biology.

To address these gaps, researchers at Xiangya Hospital have established a specialized ocular tumor biobank. This facility, the first of its kind in China, serves as a bridge between basic science and clinical application by providing standardized, well-annotated biospecimens for translational research.

Standardized Biobanking Workflow

The value of a biobank lies not just in its storage capacity but in the rigor of its collection and processing protocols. The Xiangya Ocular Tumor Bank operates under strict Standardized Operating Protocols (SOPs) to ensure the biological integrity of every sample.

Workflow for participant recruitment, specimen processing, data management, and research sharing.

The workflow encompasses four primary stages:

  1. Participant Recruitment: Patients suspected of or diagnosed with ocular tumors scheduled for surgery are informed and provide consent.
  2. Biological Specimen Processing: Tissue samples are preserved in liquid nitrogen immediately following surgery. Blood samples are processed within 30 minutes to separate plasma and whole blood components.
  3. Data Integration: Clinical variables, including demographics, imaging, and histopathology, are linked to physical samples via a digital management system.
  4. Research Sharing: A formal application and agreement process allows researchers to access these resources for pathological and translational studies.

Characterization of the Biobank Cohort

Between December 2018 and January 2020, the biobank collected 846 samples from 92 clinical cases, covering 21 distinct types of eye tumors. The collection includes 356 whole blood samples (42.1%), 324 plasma samples (38.3%), and 166 tissue samples (19.6%).

Distribution of specimen types, patient age groups, and sample counts across various eye diseases.

The cohort demonstrates a diverse demographic and diagnostic range. Age distribution shows that 50% of patients were between 31 and 60 years old, while 33% were 61 or older. The most prevalent conditions in the bank include basal cell carcinoma, lymphoma, and choroidal melanoma, alongside several undiagnosed or rare eye diseases.

Clinical Insights and Predictors of Malignancy

Beyond acting as a repository, the biobank's integrated data allowed for significant clinical analysis. Using multivariate logistic regression, the researchers identified key predictors of tumor malignancy:

  • The "Proptosis Paradox": Interestingly, proptosis (bulging of the eye) was identified as a protective factor against malignancy in this specific cohort (B = -2.534; P = 0.001). This suggests that benign orbital masses were more likely to present with visible bulging than malignant ones in this population.
  • Gender and Age: Gender was a significant predictor (B = 1.599; P = 0.025), with males exhibiting a higher prevalence of malignant tumors (87.5%). Furthermore, malignant tumors were more common in older patients (mean age 50.9) compared to those with benign tumors (mean age 41.5).
  • Laterality: Tumors were slightly more frequent in the left eye (56%) and were overwhelmingly unilateral (95%).

Future Directions

While the biobank is in its early operational phase, it provides a robust foundation for future research. The current limitations, such as a single-center sample source and the need for greater public awareness regarding biobanking, are being addressed. Future plans include expanding into a multi-center network and utilizing the preserved samples to develop patient-derived tumor xenografts (PDX) and organoids. These "mini-tumors" will allow for real-time drug sensitivity testing, moving closer to the goal of personalized medicine for ocular tumor patients.

Summary updated

Abstract

The pathogenesis and etiology of various ocular tumors remain largely unclear, limiting the development of diagnostic and treatment approaches for such tumors. Tissue samples from patients are also valuable resource to elucidate mechanisms underlying tumorigenesis. Here we present the early phase setup of an ocular tumor biobank at Xiangya Hospital. Blood and tissue samples along with associated clinical data were obtained from patients who underwent surgery in the Department of Ophthalmology of Xiangya Hospital from December 1, 2018 to January 31, 2020. Standardized operating protocols were developed for the collection, transportation, processing and preservation of ocular tumor samples. A total of 92 clinical cases suffered from 21 types of eye tumors and several undiagnosed eye diseases were covered. A total of 846 samples were preserved in the ocular tumor biobank, including 356 blood samples (42.1%), 324 plasma samples (38.3%), and 166 tissue samples (19.6%). Using the clinical data, we analyzed the prevalence of malignant ocular tumors in association with variables of age, gender, tumors' location and size, and presenting complaints of lump and proptosis. The factors predictive of malignant ocular tumors, included gender (B = 1.599; <i>P</i> = 0.025) and the symptom of proptosis (B = -2.534; <i>P</i> = 0.001). Overall, the setup of clinically-based ophthalmologic biobank could support pathological and translational research into ocular tumors.
BibTeX
@inproceedings{gao2022xiangya,
  author = {Zhaolin Gao and Jia Tan and Sha Wang and Haiyang Yu and Ziyu Zhou and Yun Zhang and Mushi Zhou and Xiaobo Xia and Fei Yao and Jufang Huang},
  title = {{The Xiangya Ocular Tumor Bank: A Disease-Specific Biobank for Advancing Translational Research Into Ocular Tumors}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2021.774624},
}
Figure